In This Issue
Cancer Discov February 1 2019 9 (2) 151-154; DOI:10.1158/2159-8290.CD-ITI9-2
Coamplification of EGFR and ERBB2 is associated with afatinib response in patients with trastuzumab-refractory esophagogastric cancer, whereas selection for MET amplification or loss of EGFR amplification is associated with resistance.
Analysis of cfDNA from 112 patients with high-grade ovarian carcinoma showed that BRCA reversion mutations may be associated with reduced clinical benefit from the PARP inhibitor rucaparib.
Chloroquine derivatives exert their antiautophagic and antitumor effects by binding palmitoyl-protein thioesterase 1 (PPT1) and inhibiting its enzymatic activity.
A CRISPR/Cas9 screen identifi es a synthetic lethal relationship between RB1 and AURKB loss in SCLC cells.
A screen of cell-cycle inhibitors reveals that RB1-mutant cancer cells are selectively dependent on Aurora kinase A.
The EIF1AX-A113spl mutation results in an alternatively spliced transcript that cooperates with RAS mutations to stabilize MYC, activate mTOR, and promote tumorigenesis.
TGFβ antagonizes IL1-driven JAK/STAT activation, which induces an inflammatory pancreatic ductal adenocarcinoma cancer-associated fi broblast (CAF) phenotype, to promote CAF heterogeneity.